CONCERTO-3

CONCERTO-3 Study: SMV + PEG-IFNα-2a + RBV for genotype 1

Izumi N, J Gastroenterol 2014;49:941-53

Anti-HCV
Simeprevir
PEG-IFNα 2a
Ribavirin
Genotype
1b
Treatment history
IFN-Experienced
Cirrhosis
No

DOWNLOAD THIS SLIDE KIT

BROWSE SLIDES

Design


* Response-guided therapy

  • SMV: 100 mg 1 capsule qd
  • PEG-IFNα-2a: 180 mg SC once weekly
  • RBV: 600 or 1000 mg/day according to body weight
  • Dosage adjustment of PEG-IFN and RBV permitted

Objective

  • Primary efficacy endpoint: SVR12 (HCV RNA < 1.2 log10 IU/ml) , with 2-sided 95% CI, significant difference vs null hypothesis proportion = 50% of success, 90% power

Baseline characteristics, and disposition

Virologic response, ITT


* One sample test for binomial distribution versus null hypothesis proportion = 50 %

  • Prevalence of baseline NS3 polymorphisms: position 170 (40.8%), 122 (36.7%), 80 (14.3%)
  • At viral relapse: 3/4 patients without baseline polymorphisms had emergence of D168V

Adverse events (entire treatment period)

Summary

  • In treatment-experienced patients with HCV genotype 1 infection who relapsed after previous IFN-based therapy, re-treatment with 12 weeks of oral SMV QD in combination with PEG-IFN + RBV achieves high SVR rate
  • SMV was generally well tolerated the incidences of serious adverse events or grade 3/4 rash or anemia were low, as were the rates of treatment discontinuations due to these adverse events